NewsWise – Houston – Using a new technology and computational method, from researchers Fred Hutch Cancer Center And University of texas md anderson cancer center Meningoma has exposed a biomarker capable of accurately predicting the results brain tumors And Breast Cancer,
In the study, published today ScienceResearchers found that a specific enzyme found on histone genes, the amount of RNA polymerase II (RNAPII) was associated with the aggression and recurrence of the tumor. RNAPII’s hyper-elevated levels on these histone genes indicate more-exist from cancer and potentially contribute to chromosome changes. These findings indicate the use of a new genomic technique as a potential cancer clinical and immoral device, which can improve the precise oncology approach.
“It has been ignored that the histone gene cell can be a rate-limit factor in cell replication and in turn, a strong indicator of tumor cell over-proliferation,” This Zheng, PhD, Co-Author and Assistant Professor said . Of Bioenformatics and computational biology MD in Anderson. “The reason for this is that the current RNA sequencing methods are unable to detect histone RNA due to their unique structure, which means that these libraries have reduced their presence significantly. Our novel approach establishes a broad ecosystem, including a new experimental technique and computational pipeline that can take advantage of biopsy samples from several cancer types to increase tumor diagnosis and disease diagnosis. ,
New technology produces better quality data from samples stored for decades.
The results of the study were made possible by a new profiling technology developed in the laboratory Steven Henicoff, Ph.D.Cum-first writer and professor in Basic Sciences Division at Fred Hutch, who formally fixed the researchers using paraffin-ambed (FFPE) samples, enables to study better study gene expression.
Tissue biopsy is usually stored for prolonged use as FFPE samples, but the sample RNA becomes rapidly unstable due to decline over time, leading to a prone to low quality gene expression data It happens.
The new technology-targeted accessible, fragmented DNA focuses on non-coding sequences under Sulabh Chromatin (Cutac), where RNAPII binds, located on the same chromosome, which they regulate, scientists, scientists straight genes from DNA The transcription allows to measure activity.
When examining clinical samples using Cutac technology in various cancer types, researchers found that tumor samples were consistently and much higher in tumor samples than normal tissue samples.
Hystone protein provides the structural support for DNA in chromosomes, acting as a spool, wrapping DNA strands around which. These proteins have been well studied, but most of the current tools to study gene expression rely on RNA sequencing. Hystone RNA is unique that its structure prevents RNA molecules from detecting in current methods.
Thus, the expression of histone genes in tumor samples can be judged significantly. Researchers envisaged that increased proliferation of cancer cells leads to a very high expression of histones, or hypertransctions to meet the additional demands of cell replication and division.
RNAPII expression relates and predicts with aggression of cancer
To test their hypothesis, researchers used Cutac profiles to examine and map RNAPII, which transfer DNA to the forearm of Messenger RNA. He studied 36 FFPE samples from patients with meningoma – a common and benign brain tumor – and about 1,300 publicly available clinical data samples and a novel computational approach to integrate this data with corresponding clinical results Used.
In tumor samples, RNAPII enzymes found on histone genes were able to differentiate between signal cancer and normal samples.
RNAPII signals on histone genes are also correlated with clinical grades in meningiomas, accurately predicting rapid recurrence as well as a tendency of the entire hand chromosome damage. FFPE samples of 13 patients of aggressive breast cancer using this technique on breast tumors also predicted the aggression of cancer.
Henicoff said, “The technique we have developed to examine the samples of preserved tumor now manifests the already unseen mechanism of aggression of cancer.” “Identifying this mechanism suggests that this may be a new test to diagnose cancer and possibly treat them.”
Zheng and colleagues plan to use this technique on FFPE samples from many cancer types for further recognition.
The research was supported by Howard Hughs Medical Institute, National Institute of Health (HG012797), and National Cancer Institute (T32CA009515). A complete list of colleagues and their revelations can be found Here,
– 30 –
) Story 2 (T) Ambergard Feed in Cancer Center – Hidan (T) Cancer (T) Healthcare (T) University of Texas MD is shown at Anderson Cancer Center
